AstraZeneca said on Friday it had appointed Alexion’s Aradhana Sarin as its new chief financial officer as it shifts existing CFO Marc Dunoyer to a new role leading the US-based drugmaker after the pair’s merger.
AstraZeneca agreed to buy Alexion in December in its largestever deal, a bet on rare-disease immunology which also includes a fast-growing cancer medicines unit and a major COVID-19 vaccine.
London-listed AstraZeneca said Sarin’s appointment was conditional upon the completion of its $39 billion buyout of Alexion.
For the latest headlines, follow our Google News channel online or via the app.
Dunoyer will become the US drugmaker’s chief executive officer while also being appointed chief strategy officer at AstraZeneca. He will leave the Anglo-Swedish company’s board but continue to report to CEO Pascal Soriot.
- Canada extends shelf life of AstraZeneca COVID-19 jab by one month
- South Korea reports first case of blood clots linked to AstraZeneca jab
- Russia declines to approve combined AstraZeneca, Sputnik V COVID-19 vaccine trials
- EU seeks to fine AstraZeneca for alleged contract breach
- Japan approves Moderna, AstraZeneca COVID-19 vaccines
- Study shows AstraZeneca COVID-19 vaccine works well as third booster: FT
- India says ‘minuscule’ clotting cases after AstraZeneca vaccine
- Ireland considering giving AstraZeneca, J&J vaccines to ages 40-49